Abstract Submission
Important Deadlines
Call for Abstracts Submission Opens July 1st 2023 | July 1st 2023 |
---|---|
Abstract Submission Deadline | 23:59 JST on October 16th 2023 |
Notification of Acceptance/Rejection | December 8th 2023 |
Submission Guidelines
- Abstracts will be accepted in English only
- All abstracts must not exceed 500 words
- A table or figure will count as 150 words
- The total word count does not include the title, authors’ details or references
- The name of the presenting author must appear first in the list of authors
- An international panel of reviews will review all abstracts anonymously
- There is no fee for submitting an abstract
- There is no limit to the number of poster abstracts you may submit
- CINP recommends using the NbN nomenclature for psychotropics (http://nbn2r.com)
Abstract submissions must be structured with the following:
- Background
- Aims & Objectives
- Method
- Results
- Discussion & Conclusion
- References – Use Harvard style, where each reference is numbered in order of use
- Keywords – Mandatory to include three
Presentation Types
- Oral Presentation: A limited number of abstracts will be selected as 15-min oral presentations (12 minutes presentation plus 3 minutes of Q&A) in one of the Oral Abstract sessions. If you are not comfortable providing an oral presentation, please only select poster presentation during submission.
- Poster Presentation: Abstracts not selected for oral presentation will be provided a poster presentation. Top rated posters will be selected as 5-minute presentations (3 minutes presentation plus 2 minutes Q&A) in one of the Data Blitz sessions.
Submission Topics
The CINP International Scientific Programme Committee welcomes abstracts that link the
latest, and ground-breaking, preclinical developments with the clinical research on a given topic.
Through the free and open exchange of ideas, CINP supports a strong focus on new approaches to the
development and assessment of CNS pharmaceuticals by researchers working in both academia and
industry.
Please find below the list of topics:
Topic 1: Research | Topic 2: By Disorder | Topic 3: By Drug Methodology |
---|---|---|
• Clinical | • Addiction Disorders | • Animal Models |
• Preclinical | • Anxiety Disorders | • Anxiolytics |
• Translational | • Attention Deficit Disorders | • Brain Stimulation |
• Others | • Autism | • Computational Neuroscience | • Bipolar Disorders | • Drugs for Bipolar Disorders |
• Childhood & Adolescent Disorders | • Drugs for Depression | |
• COVID-19 | • Drugs for Insomnia | |
• Dementia | • Drugs for Psychosis | |
• Depression | • Ethics of Psychopharmacology | |
• Eating Disorders | • Genetics | |
• Epilepsy | • History of Psychopharmacology | |
• Obsessive-Compulsive Disorders | • Imaging | |
• Pain | • Molecular Neurobiology/Pharmacology | |
• Panic Disorders | • Neuropathology/Post-Mortem Studies | |
• Personality Disorders | • Neurophysiology | |
• Post-Traumatic Stress Disorders | • Oriental Medicine | |
• Premenstrual Dysphoric Disorder | • Pharmacoeconomics | |
• Schizophrenia | • Pharmacogenetics/Kinetics | |
• Sexual Disorders | • Psychoneuroimmunology | |
• Sleep Disorders | • Transcultural Psychopharmacology | |
• Suicide | • Others | |
• Others |